Akero Therapeutics Expands Leadership Team

Kitty Yale appointed chief development officer SAN FRANCISCO, Oct. 17, 2018 -- (Healthcare Sales & Marketing Network) -- Akero Therapeutics, Inc., a biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH) a... Biopharmaceuticals, Personnel Akero Therapeutics, non-alcohol steatohepatitis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news